transient receptor potential cation channel subfamily C member 4Genealiases: HTRP-4 · HTRP4 · TRP4
Q-omics provides the consensus-scored TRPC4 profile across patient tissues and cancer cell-line models. TRPC4 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TRPC4 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, TRPC4 RNA expression shows 16,031 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, HNSC, and TGCT as cancer lineages where TRPC4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPC4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPC4 survival associations across molecular data types. TRPC4 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPC4 RNA expression–survival associations across cancer types. High TRPC4 expression shows unfavorable associations in KIRP, MESO, BLCA and UVM, but favorable associations in KIRC and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for TRPC4 RNA expression.
This table summarizes TRPC4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRPC4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPC4 shows lower tumor expression in UCEC, BLCA and LUSC and higher tumor expression in HNSC, BRCA and KIRC. The HNSC box plot shows higher TRPC4 RNA expression in tumor versus normal tissue (log2 FC = +0.836, t-test p < 0.001).
This table shows molecular features associated with TRPC4 in patient tissues and cancer cell lines. In patient samples, TRPC4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPC4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
